PUBLISHER: IMARC | PRODUCT CODE: 1819859
PUBLISHER: IMARC | PRODUCT CODE: 1819859
The global immunodiagnostics market size reached USD 20.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 35.3 Billion by 2033, exhibiting a growth rate (CAGR) of 6.5% during 2025-2033.
Immunodiagnostics refers to an in-vitro diagnostic technology that uses antigen-antibody reaction for the detection of infectious and chronic diseases. It involves the use of radiological, fluorescent or color-forming enzymes and probes for the identification of antibodies that aid in enhancing the targeting range to identify disease progression. Immunodiagnostics also uses various reagents, instruments and software-based solutions for enzyme-linked immunosorbent assay, chemiluminescence, radioimmunoassay and rapid testing. These solutions are widely used for diagnosing diseases, such as cancer and autoimmune, respiratory, endocrine and oncological disorders, along with forensic psychology and environmental and food analysis. As a result, immunodiagnostics finds extensive applications across hospitals, clinical laboratories and research and academic institutes.
The increasing prevalence of chronic medical ailments and infections among the masses is one of the key factors driving the market growth. Moreover, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the growth of the market. There is also an escalating awareness among the consumers regarding the available treatment alternatives for ailments, such as hepatitis B, diabetes and cancer, which is positively impacting the demand for immunodiagnostics kits, assays and analyzers. Additionally, various technological advancements, such as the development of next-generation immunodiagnostics platforms, are anticipated to drive the market toward growth. These advanced point-of-care testing (POCT) systems offer enhanced diagnostic facilities for sepsis, acute cardiac infractions and other medical disorders with higher mortality rates. Other factors, including the increasing requirement for personalized medicines among the masses, along with extensive improvements in the healthcare infrastructure, especially in the developing economies, are anticipated to drive the market toward growth.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arkray Inc., bioMerieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., F. Hoffmann-La Roche AG, Immunodiagnostic Systems Holdings PLC, Johnson & Johnson, Siemens AG, Sysmex Corporation and Thermo Fisher Scientific Inc.